曲妥珠单抗博替丁相关角膜不良事件的临床特征:载荷驱动的上皮病变与神经病变
本研究为回顾性病例系列,纳入8例接受曲妥珠单抗博替丁治疗的HER2突变或阳性实体瘤成人患者(15眼),评估角膜不良事件。结果显示所有患者均出现角膜不良事件,平均视觉损害发生时间为用药后37.25±5.90天,症状严重程度峰值在82.75±14.26天,表现为干眼、角膜上皮病变和神经损伤。
要点
- 曲妥珠单抗博替丁治疗患者均出现角膜不良事件,平均视觉损害发生时间为37.25±5.90天。
- 所有患者出现干眼,Schirmer试验、泪膜破裂时间和泪河高度均显著下降。
- 角膜上皮病变包括假微囊肿、点状上皮病变、弥漫性点状上皮病变和涡状角膜病变,IVCM显示神经毒性损伤。
核心结论
- 曲妥珠单抗博替丁与视觉损害、角膜上皮病变和神经损伤相关。
- 眼科医生与肿瘤科医生密切合作对于早期发现ADC治疗相关角膜不良事件至关重要。
研究设计与样本
- 回顾性病例系列,纳入8例接受曲妥珠单抗博替丁治疗的HER2突变或HER2阳性实体瘤成人患者(15眼)。
主要发现
- 所有8例患者均发生角膜不良事件。
- 平均视觉损害发生时间为曲妥珠单抗博替丁开始后37.25±5.90天,症状严重程度峰值在82.75±14.26天。
- 眼表疾病指数评分从基线5.73±2.67升高至严重程度峰值时的65.10±13.26。
- 所有患者出现干眼,Schirmer试验结果从8.94±1.66 mm降至4.20±1.58 mm,泪膜破裂时间从9.63±1.21秒缩短至3.37±1.61秒,泪河高度从0.23±0.04 mm降至0.14±0.02 mm。
- 裂隙灯显微镜和荧光素染色显示假微囊肿、点状上皮病变、弥漫性点状上皮病变和涡状角膜病变;IVCM显示浅层上皮囊样高反射结构、翼状细胞和基底细胞葡萄样高反射簇、细胞排列紊乱以及神经毒性损伤(基底神经变薄、神经密度降低、基底神经丛局灶性断裂)。
临床怎么用
- 眼科医生与肿瘤科医生应密切合作,早期发现曲妥珠单抗博替丁相关角膜不良事件,以改善临床结局和患者生活质量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: HER2-targeted antibody-drug conjugates (ADCs) demonstrate significant efficacy in HER2-mutated or HER2-positive tumors but may cause ocular adverse events (AEs), particularly corneal epitheliopathy and blurred vision. This study aimed to characterize the clinical features of trastuzumab botidotin (a HER2-targeted ADC)-related corneal AEs. DESIGN: Retrospective case series. SUBJECTS: Eight adult patients (15 eyes) with HER2-mutated or HER2-positive solid tumors treated with trastuzumab botidotin. METHODS: Assessments included best-corrected visual acuity, Ocular Surface Disease Index, Schirmer's test, tear break-up time, tear meniscus height, and corneal fluorescein staining. In vivo confocal microscopy (IVCM) was performed to evaluate cellular structures and confirm lesion characteristics. MAIN OUTCOME MEASURES: Corneal AEs associated with trastuzumab botidotin and their clinical features. RESULTS: Corneal AEs occurred in all eight patients. The mean time to visual impairment onset was 37.25 ± 5.90 days after trastuzumab botidotin initiation, with symptom severity peaking at 82.75 ± 14.26 days. Ocular Surface Disease Index scores increased from 5.73 ± 2.67 at baseline to 65.10 ± 13.26 at peak severity. Trastuzumab botidotin caused dry eye in all patients (n = 8), resulting in reduced Schirmer's test results (from 8.94 ± 1.66 mm to 4.20 ± 1.58 mm), shortened tear break-up time (from 9.63 ± 1.21 seconds to 3.37 ± 1.61 seconds), and decreased tear meniscus height (from 0.23 ± 0.04 mm to 0.14 ± 0.02 mm). Slit-lamp microscopy and fluorescein staining revealed that trastuzumab botidotin induced distinct corneal epitheliopathy, characterized by pseudomicrocysts, punctate epitheliopathy, diffuse punctate epitheliopathy, and vortex keratopathy. IVCM correlated these findings, showing cyst-like hyperreflective structures in the superficial epithelium, grape-like hyperreflective clusters in wing cells and basal cells, and associated cellular disorganization. IVCM demonstrated neurotoxic damage, characterized by thinning of subbasal nerves, decreased nerve density, and focal discontinuities in the subbasal nerve plexus. CONCLUSIONS: Trastuzumab botidotin was associated with visual impairment, corneal epitheliopathy, and nerve damage. Close collaboration between ophthalmologists and oncologists is crucial for early detection of corneal AEs related to ADC therapy, thereby improving clinical outcomes and patient quality of life.
引用
- Zhang Y, Tang G, Zhang J, et al. Clinical Features of Corneal Adverse Events Associated With Trastuzumab Botidotin: Payload-Driven Epitheliopathy and Neuropathy. Am J Ophthalmol. 2026. PMID: 42176831. doi:10.1016/j.ajo.2026.05.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。